Expectations of the ability of 4 vaccines to confront the new Corona strain

At least four companies expected that the vaccines they produced to prevent the emerging corona virus (Covid-19) will be effective and resilient against a new strain of the rapidly spreading virus in Britain and are conducting tests that will provide confirmation of their expectations in the next few weeks.

Ugur Shaheen, chief executive of the German company Biontech that took less than a year, in partnership with the US company Pfizer, to obtain approval for the vaccine, said he expected the vaccine to remain effective.

The German companies Moderna, Corvac and British AstraZeneca also believe that the vaccines they have developed will succeed in facing the new strain of the virus that has caused chaos in Britain, which led to a wave of travel bans that disrupts trade with Europe and threatens to deepen Britain's isolation from the continent.

The German company, Curvac, began the final phase of clinical trials of its vaccine last week and is constantly reviewing strains that the company said is common with the spread of the virus.

Britain's chief scientific adviser, Patrick Vallance, said the vaccines appeared to be sufficient to generate an immune response to the coronavirus strain.

The World Health Organization announced earlier that it will hold a meeting of members to discuss strategies to address the mutation.

Follow our latest local and sports news, and the latest political and economic developments via Google news